Geneva (ots/PRNewswire) - - New Research Finds Most Australians Consider So-Called 'Plain' Packaging Ineffective, with Eight out of Ten Believing the Government Would Ignore Evidence if it Contradicted its Preferred Policy - Australians Concerned Regulation May Spread to Other Categories CanvasU, commissioned by JTI ...
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (http://www.insightec.com/), the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, announced today that the Taiwanese Food and Drug Administration (TFDA) has approved its Exablate Neuro system for the treatment of essential tremor in patients who do not respond to ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
London (ots/PRNewswire) - ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment ...
Amsterdam (ots/PRNewswire) - - Two year study* found that clinicians' use of Azurion enabled significant reductions in procedure time, in-lab patient preparation time, post-procedure lab time and enhanced staff experience - Improvements correspond to the ability to treat one additional patient per interventional lab ...
Basel, Switzerland (ots/PRNewswire) - Today, Ascensia Diabetes Care, a leading diabetes care company, is showing its support for World Diabetes Day 2017 by publishing 30 portraits of inspiring women who are making significant contributions to advancing diabetes care. The theme of World Diabetes Day is Women and Diabetes, and through this initiative, Ascensia aims to ...
Darmstadt, Germany (ots/PRNewswire) - - New pen is easy-to-learn and easy-to-use, supporting the one in six couples affected by infertility in the U.S.[1] - Insights of patients, nurses and doctors helped to evolve the product Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and ...
Amsterdam (ots/PRNewswire) - myTomorrows announces that Ronald Plasterk, a renowned molecular geneticist and until recently Dutch Minister of the Interior and Kingdom Relations, joins the company as Chief Scientific Officer, effective 1 December 2017. Plasterk will primarily focus on creating academic partnerships to address specific areas of unmet medical need, supporting myTomorrows' aim to facilitate early access to ...
Darmstadt, Germany (ots/PRNewswire) - - First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe - Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years Merck, a leading science and technology company, today announced that the National Institute ...
Zurich (ots/PRNewswire) - Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration ...
Stockholm (ots/PRNewswire) - OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
Berlin (ots/PRNewswire) - - 'Vaccination apathy' is a key barrier to protecting the community against infectious disease, according to global health experts - By 2060, 30% of Europeans will be aged 65 years or over[1] - a life-course approach to immunisation, including adult vaccination, is a cost-effective method ...
San Diego and London (ots/PRNewswire) - Findings from a new multi-country GSK survey, released today to coincide with the 2017 American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting (ACR/AHRP), reveal that patients with systemic lupus erythematosus (SLE) often self-manage ...
Glasgow, Scotland (ots/PRNewswire) - Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.[1] The analysis was presented today at the International Society for Pharmacoeconomics and Outcomes Research ...
Denver (ots/PRNewswire) - One-year results from the REDUCE trial reported at TCT 2017 OrbusNeich has reported results from the REDUCE trial today in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, providing fresh insights into the ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for patients with ulcerative colitis or Crohn's disease Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced the ...
Washington (ots/PRNewswire) - Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management ...
Denver (ots/PRNewswire) - One-year results from the pivotal HARMONEE trial reported at TCT 2017 New results from the HARMONEE Japan/US Registration Trial, reported by OrbusNeich today in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, ...
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (https://www.insightec.com/), the leader in MR-guided Focused Ultrasound (MRgFUS), has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation. Exablate Neuro is an innovative medical technology that uses focused ultrasound coupled with MR imaging (MRgFUS), to precisely target and treat areas deep ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. based media. - Grant awarded across three research projects focused on prediction and defining characteristics of multiple sclerosis - Investment of EUR5 million in multiple sclerosis research funding as awards mark fifth year Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (http://www.insightec.com), the world leader of MR-guided Focused Ultrasound announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia symptoms or motor ...
Darmstadt, Germany (ots/PRNewswire) - - Multiple sclerosis diagnosis has a profound impact on life choices including education, career, family planning and relationships - Almost 90% of women say multiple sclerosis played a role in their separation or divorce following diagnosis - Policy interventions could help address significant gender-specific challenges Merck, a ...
Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The ...
Hong Kong (ots/PRNewswire) - - Program to include late-breaking presentation of REDUCE clinical trial - Data on more than 5,000 patients to be presented OrbusNeich, a global company specialising in the provision of life-changing vascular solutions, has today announced a schedule of events at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, ...